Get alerts for new trials in your area by subscribing now
Active & Responsive
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
for
Triple Negative Breast Cancer (TNBC),
Location: 9 recruiting locations
Sponsor: Boundless Bio
Sex: All
Age: 18+
Code: NCT05827614
Phase1, Recruiting
Active & Responsive
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors